SCHEMBL5022258

SCHEMBL5022258

Cc1ccc(-c2nc(NC(=O)C(C)c3cccnc3)cc(-c3ccccn3)n2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.43
ADORA2A P29274 11/20 0.43
ADORA1 P30542 11/20 0.43
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
MCL1 Q07820 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016204 0.86 ADORA3 (0.48) POLBADORA2AADORA1KDM4EALDH1A1
SCHEMBL5022617 0.85 ADORA2A (0.59) POLBADORA2AADORA1KDM4EALDH1A1
SCHEMBL5017601 0.81 ADORA2A (0.52) ADORA2AADORA1MKNK1
SCHEMBL5017763 0.81 ADORA2A (0.46) POLBADORA2AADORA1LMNATSHR
SCHEMBL5016304 0.81 ADORA2A (0.55) POLBADORA2AADORA1ALDH1A1MAPT
SCHEMBL5026350 0.79 ADORA2A (0.59) ADORA2AADORA1
SCHEMBL4962442 0.77 ADORA2A (0.55) POLBADORA2AADORA1KDM4EALDH1A1
SCHEMBL5022903 0.76 ADORA2A (0.54) POLBADORA2AADORA1KDM4EALDH1A1
SCHEMBL5022422 0.75 ADORA2A (0.53) POLBADORA2AADORA1KDM4EALDH1A1
SCHEMBL8257005 0.73 ADORA2A (0.46) POLBADORA2AADORA1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 POLB 1317/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.